We are live on ! Find out more
XFOR icon

X4 Pharmaceuticals
XFOR

40 hedge funds and large institutions have $14.9M invested in X4 Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

220% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 5

14% more funds holding

Funds holding: 35 → 40 (+5)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.04% less ownership

Funds ownership: 0.4% → 0.36% (-0.04%)

67% less capital invested

Capital invested by funds: $45.5M → $14.9M (-$30.6M)

Holders
40
Holders Change
+5
Holders Change %
+14.29%
% of All Funds
0.91%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
7
Increased
16
Reduced
5
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
+$296K
2
AIM
Alambic Investment Management
California
+$287K
3
State Street
State Street
Massachusetts
+$145K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$117K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$110K

Top Sellers

Rank Fund Capital Flow
1
AI
Alphabet Inc
California
-$9.83M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.61M
3
JP Morgan Chase
JP Morgan Chase
New York
-$168K
4
UBS Group
UBS Group
Switzerland
-$32.7K
5
TRCT
Tower Research Capital (TRC)
New York
-$2.54K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$3.24M – – –
O
2
OrbiMed
New York
$3.03M – – –
PVMCV
3
Polaris Venture Management Co V
Massachusetts
$3.03M – – –
SHI
4
SV Health Investors
Massachusetts
$3.03M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$463K – – –
BlackRock
6
BlackRock
New York
$368K +$6.79K +16 +1%
AIM
7
Alambic Investment Management
California
$217K +$287K +676 +1,009%
State Street
8
State Street
Massachusetts
$205K +$145K +343 +94%
Citigroup
9
Citigroup
New York
$205K +$296K +698 +17,450%
First Eagle Investment Management
10
First Eagle Investment Management
New York
$201K – – –
GIM
11
Granahan Investment Management
Massachusetts
$169K +$8.48K +20 +4%
BCM
12
Bridgeway Capital Management
Texas
$100K +$43.3K +102 +42%
Jacobs Levy Equity Management
13
Jacobs Levy Equity Management
New Jersey
$94K +$110K +259 +405%
Northern Trust
14
Northern Trust
Illinois
$83K +$2.12K +5 +2%
Acadian Asset Management
15
Acadian Asset Management
Massachusetts
$81K +$117K +277 New
Geode Capital Management
16
Geode Capital Management
Massachusetts
$72K +$11.5K +27 +12%
Two Sigma Investments
17
Two Sigma Investments
New York
$58K +$84K +198 New
OAM
18
Oxford Asset Management
United Kingdom
$43K +$58.1K +137 New
VF
19
Virtu Financial
New York
$37K +$53.9K +127 New
Squarepoint
20
Squarepoint
New York
$26K +$37.7K +89 New
Bank of New York Mellon
21
Bank of New York Mellon
New York
$25K -$424 -1 -1%
Morgan Stanley
22
Morgan Stanley
New York
$22K +$8.06K +19 +35%
New York State Common Retirement Fund
23
New York State Common Retirement Fund
New York
$19K – – –
Deutsche Bank
24
Deutsche Bank
Germany
$19K +$7.21K +17 +35%
CHP
25
Cable Hill Partners
Oregon
$17K +$19.1K +45 +409%
1
2

XFOR Hedge Fund Activity: Q3 2018 in Review

40 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q3 2018, worth a combined $14.9M — down 67% from $45.5M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new XFOR positions and 2 closed out — a net gain of 5 holders — while 16 added to existing stakes and 5 trimmed.

The largest buyer was Citigroup, adding an estimated $296K. The largest seller was Alphabet Inc, exiting entirely with an estimated $9.83M sold.

  • 40 institutional investors held X4 Pharmaceuticals (XFOR) as of Q3 2018, up from 35 in Q2 2018.
  • Funds reported $14.9M of X4 Pharmaceuticals stock for Q3 2018, down 67% quarter-over-quarter.
  • 7 funds opened new X4 Pharmaceuticals positions in Q3 2018 and 2 closed out, a net change of +5 holders.
  • The largest X4 Pharmaceuticals buyer in Q3 2018 was Citigroup, an estimated $296K added.
  • The largest X4 Pharmaceuticals seller in Q3 2018 was Alphabet Inc, an estimated $9.83M sold.

Based on aggregated 13F filings for Q3 2018.